Luteolin, a natural flavone found in various fruits and vegetables, has shown significant anticancer potential through mechanisms such as inducing apoptosis, cell cycle arrest, and inhibiting angiogenesis and metastasis. It modulates multiple signaling pathways in tumor cells, exhibits antioxidant properties, and can be used in combination with chemotherapy to mitigate adverse effects. Luteolin has demonstrated efficacy in various cancers, including breast, colorectal, lung, prostate, liver, skin, pancreatic, oral, and gastric cancers. It also exhibits neuroprotective and anti-inflammatory properties. Recent studies highlight its potential as a synergistic agent to overcome drug resistance in cancer cells. Luteolin's anticancer effects are attributed to its ability to target multiple molecular sites and influence key pathways involved in cancer progression. It has been shown to inhibit the epithelial-to-mesenchymal transition (EMT), reduce oxidative stress, and modulate signaling pathways such as PI3K/Akt and NF-κB. Luteolin is naturally present as a glucoside and has been studied for its biosynthesis and mechanisms of action. It has been found to inhibit the growth of cancer cells, induce apoptosis, and suppress metastasis. Luteolin's potential as a chemopreventive agent and its role in cancer treatment are supported by numerous studies. Additionally, luteolin has shown promise in other areas such as cardiovascular diseases, diabetes, and inflammation, highlighting its broad therapeutic applications. However, its toxicity and optimal dosing require further investigation to ensure its safe and effective use in clinical settings.Luteolin, a natural flavone found in various fruits and vegetables, has shown significant anticancer potential through mechanisms such as inducing apoptosis, cell cycle arrest, and inhibiting angiogenesis and metastasis. It modulates multiple signaling pathways in tumor cells, exhibits antioxidant properties, and can be used in combination with chemotherapy to mitigate adverse effects. Luteolin has demonstrated efficacy in various cancers, including breast, colorectal, lung, prostate, liver, skin, pancreatic, oral, and gastric cancers. It also exhibits neuroprotective and anti-inflammatory properties. Recent studies highlight its potential as a synergistic agent to overcome drug resistance in cancer cells. Luteolin's anticancer effects are attributed to its ability to target multiple molecular sites and influence key pathways involved in cancer progression. It has been shown to inhibit the epithelial-to-mesenchymal transition (EMT), reduce oxidative stress, and modulate signaling pathways such as PI3K/Akt and NF-κB. Luteolin is naturally present as a glucoside and has been studied for its biosynthesis and mechanisms of action. It has been found to inhibit the growth of cancer cells, induce apoptosis, and suppress metastasis. Luteolin's potential as a chemopreventive agent and its role in cancer treatment are supported by numerous studies. Additionally, luteolin has shown promise in other areas such as cardiovascular diseases, diabetes, and inflammation, highlighting its broad therapeutic applications. However, its toxicity and optimal dosing require further investigation to ensure its safe and effective use in clinical settings.